Endocrinology, Vol 132, 1577-1584, Copyright © 1993 by Endocrine Society

ARTICLES

The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats

DB Kimmel, RP Bozzato, KA Kronis, T Coble, D Sindrey, P Kwong and RR Recker
Center for Hard Tissue Research, Creighton University, Omaha, Nebraska 68131.

The purpose of this study was to evaluate the dose-effect relationship of recombinant human PTH [hPTH-(1-84)] and synthetic human PTH [sPTH-(1- 34)] for the skeleton of estrogen-deplete osteopenic rats. Ex vivo densitometry of regionalized whole femurs and histomorphometry of proximal tibial cancellous bone were the end points. Retired breeder female rats, aged 6-7 months, were used. Ten were killed at baseline, and the rest were ovariectomized (OVX). On day 42, a pre-PTH treatment OVX group was killed. The rest were then treated by daily sc injection with hPTH (0, 1.55, 15.5, or 155 micrograms/kg BW.day) or sPTH (0.55, 5.5, or 55 micrograms/kg BW.day) and killed on day 70. The level of cancellous bone mineral was lower in pretreatment OVX rats than at baseline. It was higher in rats treated with 15.5-155 micrograms/kg.day hPTH and 5.5-55 micrograms/kg.day sPTH than in pretreatment and vehicle- treated OVX rats. Cancellous bone volume was also lower both 42 and 70 days after OVX. Although hPTH did not affect cancellous bone volume, treatment with 5.5-55 micrograms/kg.day sPTH caused higher bone volume than in either pretreatment or vehicle-treated OVX rats. Trabecular number declined after OVX and did not change with PTH treatment. In contrast, trabecular thickness declined after OVX, but was higher after 15.5-155 micrograms/kg.day hPTH and 5.5-55 micrograms/kg.day sPTH treatment. In OVX rats, the amount of mineralizing surface was greater by day 42 and fell toward control levels by day 70. It was greater in rats treated with 15.5-155 micrograms/kg.day hPTH or 5.5-55 micrograms/kg.day sPTH than in vehicle-treated OVX rats. On a molar basis, sPTH was modestly more potent than hPTH. Osteoclast surface was not affected by PTH treatment. Treating estrogen-deplete osteopenic adult rats for 28 days with 15.5-155 micrograms/kg.day hPTH or 5.5-55 micrograms/kg.day sPTH increases trabecular thickness, but not trabecular number, to cause a rise in bone mass. The extent of mineralizing surface rises without a change in resorption surface. The marked rise in mineralizing surfaces suggests that extended in vivo treatment with PTH activates osteogenic precursor cells near once quiescent surfaces to become osteoblasts.

This article has been cited by other articles:

				J. S. Finkelstein, J. J. Wyland, B. Z. Leder, S.-A. M. Burnett-Bowie, H. Lee, H. Juppner, and R. M. Neer Effects of Teriparatide Retreatment in Osteoporotic Men and Women J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2495 - 2501. [Abstract] [Full Text] [PDF]

				S. Kurtoglu, T. Gunes, E. Koklu, O. Bastug, O. Canoz, M. Kula, F. Bastug, and I. Gunes Influence of Maternal Nicotine Exposure on Neonatal Rat Bone: Protective Effect of Pentoxifylline Experimental Biology and Medicine, March 1, 2007; 232(3): 398 - 405. [Abstract] [Full Text] [PDF]

				S. P Shrader and K. R Ragucci Parathyroid Hormone (1-84) and Treatment of Osteoporosis Ann. Pharmacother., September 1, 2005; 39(9): 1511 - 1516. [Abstract] [Full Text] [PDF]

				Y. M. Alkhiary, L. C. Gerstenfeld, E. Krall, M. Westmore, M. Sato, B. H. Mitlak, and T. A. Einhorn Enhancement of Experimental Fracture-Healing by Systemic Administration of Recombinant Human Parathyroid Hormone (PTH 1-34) J. Bone Joint Surg. Am., April 1, 2005; 87(4): 731 - 741. [Abstract] [Full Text] [PDF]

				B. J. Arey, R. Seethala, Z. Ma, A. Fura, J. Morin, J. Swartz, V. Vyas, W. Yang, J. K. Dickson Jr., and J. H. M. Feyen A Novel Calcium-Sensing Receptor Antagonist Transiently Stimulates Parathyroid Hormone Secretion in Vivo Endocrinology, April 1, 2005; 146(4): 2015 - 2022. [Abstract] [Full Text] [PDF]

				T. M. Murray, L. G. Rao, P. Divieti, and F. R. Bringhurst Parathyroid Hormone Secretion and Action: Evidence for Discrete Receptors for the Carboxyl-Terminal Region and Related Biological Actions of Carboxyl- Terminal Ligands Endocr. Rev., February 1, 2005; 26(1): 78 - 113. [Abstract] [Full Text] [PDF]

				J. L. Vahle, G. G. Long, G. Sandusky, M. Westmore, Y. L. Ma, and M. Sato Bone Neoplasms in F344 Rats Given Teriparatide [rhPTH(1-34)] Are Dependent on Duration of Treatment and Dose Toxicol Pathol, June 1, 2004; 32(4): 426 - 438. [Abstract] [PDF]

				A. B. Hodsman, D. A. Hanley, M. P. Ettinger, M. A. Bolognese, J. Fox, A. J. Metcalfe, and R. Lindsay Efficacy and Safety of Human Parathyroid Hormone-(1-84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5212 - 5220. [Abstract] [Full Text] [PDF]

				M. Sato, J. Vahle, A. Schmidt, M. Westmore, S. Smith, E. Rowley, and L. Y. Ma Abnormal Bone Architecture and Biomechanical Properties with Near-Lifetime Treatment of Rats with PTH Endocrinology, September 1, 2002; 143(9): 3230 - 3242. [Abstract] [Full Text] [PDF]

				E. F. Nemeth, E. G. Delmar, W. L. Heaton, M. A. Miller, L. D. Lambert, R. L. Conklin, M. Gowen, J. G. Gleason, P. K. Bhatnagar, and J. Fox Calcilytic Compounds: Potent and Selective Ca2+ Receptor Antagonists That Stimulate Secretion of Parathyroid Hormone J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 323 - 331. [Abstract] [Full Text] [PDF]

				S. Matsushima, M. Hoshimoto, M. Torii, K. Ozaki, and I. Narama Iron Lactate-Induced Osteopenia in Male Sprague-Dawley Rats Toxicol Pathol, October 1, 2001; 29(6): 623 - 629. [Abstract] [PDF]

				N. Miyakoshi, Y. Kasukawa, T. A. Linkhart, D. J. Baylink, and S. Mohan Evidence That Anabolic Effects of PTH on Bone Require IGF-I in Growing Mice Endocrinology, October 1, 2001; 142(10): 4349 - 4356. [Abstract] [Full Text] [PDF]

				S. E. Hahn, M. Yu, S. Tong, A. A.T. Geisterfer-Lowrance, D. Sindrey, and D. K.H. Lee Development of an In Vitro Screening Assay for Compounds that Increase Bone Formation J Biomol Screen, December 1, 1999; 4(6): 363 - 371. [Abstract] [PDF]

				M. Sato, G. Q. Zeng, E. Rowley, and C. H. Turner LY353381{middle dot}HCl: An Improved Benzothiophene Analog with Bone Efficacy Complementary to Parathyroid Hormone-(1-34) Endocrinology, November 1, 1998; 139(11): 4642 - 4651. [Abstract] [Full Text] [PDF]

				H. A. Simmons, C. M. Pirie, D. D. Thompson, and H. Z. Ke Parathyroid Hormone (1-34) Increased Total Body Bone Mass in Aged Female Rats J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 341 - 344. [Abstract] [Full Text]

				J. W. M. Chow, S. Fox, C. J. Jagger, and T. J. Chambers Role for parathyroid hormone in mechanical responsiveness of rat bone Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E146 - E154. [Abstract] [Full Text] [PDF]

				M. Sato, G. Q. Zeng, and C. H. Turner Biosynthetic Human Parathyroid Hormone (1-34) Effects on Bone Quality in Aged Ovariectomized Rats Endocrinology, October 1, 1997; 138(10): 4330 - 4337. [Abstract] [Full Text] [PDF]

				B. h. Sun, M. Mitnick, C. Eielson, G. Q. Yao, I. Paliwal, and K. Insogna Parathyroid Hormone Increases Circulating Levels of Fibronectin in Vivo: Modulating Effect of Ovariectomy Endocrinology, September 1, 1997; 138(9): 3918 - 3924. [Abstract] [Full Text] [PDF]